索拉非尼托西酯

[CAS號] 475207-59-1
[分子量] 637.03
[分子式] C21H16ClF3N4O3.C7H8SO3  
[外觀]白色至類白色結晶性粉末
[密度] 1.454 g / cm3
[沸點] 523.3°C在760 mmHg
[閃點] 270.3°C
關於甲苯磺酸索拉非尼
Sorafenib tosylate is a new multi-targeted anti-tumor drug developed by Bayer AG in Germany that can act on both tumor cells and tumor blood vessels.甲苯磺酸索拉非尼是德國拜耳公司開發的新型多靶點抗腫瘤藥物，可同時作用於腫瘤細胞和腫瘤血管。 It has a dual antitumor effect: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF / MEK / ERK, and can also inhibit the growth of tumor cells by inhibiting VEGF and platelet-derived growth factor (PDGF) receptors Blocking the formation of neovascularization, indirectly inhibiting the growth of tumor cells.它具有雙重抗腫瘤作用：它可以通過阻斷RAF / MEK / ERK介導的細胞信號通路直接抑制腫瘤細胞的增殖，還可以通過抑制VEGF和血小板源性生長因子（PDGF）抑制腫瘤細胞的生長。 ）受體阻斷新血管形成的形成，間接抑制腫瘤細胞的生長。
甲苯磺酸索拉非尼用於治療原發性腎癌，晚期原發性肝癌和放射性碘耐藥的晚期甲狀腺癌。